After reviewing our recently published study (Huang et al., 2010) , Cohick and Bhattacharjee (2011) suggest stopping the administration of pyridoxine once the hemoglobin level reaches a tolerable level (10-12 g/dl) to prevent a deleterious rise in ferritin levels. Although anemia is frequently associated with rheumatoid arthritis (RA) (Wilson et al., 2004) , none of our patients had anemia; the short disease duration (2.6 ± 1.6 years) of our patients may have not yet influenced their hematological measurement. Although serum ferritin level was not measured, we did monitor patient's red blood cell (RBC), hemoglobin and hematocrit levels during the supplementation period. The results are listed in Table 1 . At baseline (week 0), RBC, hemoglobin and hematocrit were normal and there were no significant differences between the two groups. After 12 weeks of vitamin supplementation, RBC, hemoglobin and hematocrit levels significantly decreased in the vitamin B6 group. It was worth noting that plasma pyridoxal 5'-phosphate (PLP) was not correlated with RBC (b ¼ À1.5 Â 10
, P ¼ 0.51) concentrations after adjusting for age, gender and serum creatinine levels in our patients with RA. It seemed that supplementation of vitamin B6 did not result in an increase in hemoglobin concentrations in our patients with RA. This is in contrast with the observation of Cohick and Bhattacharjee in their study.
The data presented by Cohick and Bhattacharjee pertain to a 65-year-old African American woman with RA and anemia whose high serum ferritin level was observed only once in their 8 years of follow-up. As ferritin levels were observed to be elevated in patients with RA (Palermo et al., 1986; Yildirim et al., 2004) as a part of acute-phase reaction, it could not simply be concluded that the high response of serum ferritin was definitely due to pyridoxine supplementation. In addition, there might be a possibility that a different response of hematological parameters exist among different ethnic groups after a high dose of vitamin B6 supplementation. Further studies are warranted to clarify the effect of vitamin B6 supplementation on ferritin levels in RA patients with or without anemia.
In the course of RA disease, cytokines are implicated in each phase of the pathogenesis of RA, by promoting autoimmunity (Mclnnes and Schett, 2007) . The increased production of cytokines may mediate a decrease in erythropoietin response in the bone marrow, thereby leading to anemia even in the presence of adequate iron stores (Wilson et al., 2004) . Inadequate erythropoiesis might be resolved, as a high dose (100 mg/day) of vitamin B6 supplementation could suppress proinflammatory cytokines (that is, interleukin-6, tumor necrosis factor-a) in patients with RA. At this point, we do not expect that vitamin B6 administration brought about a deleterious rise in serum ferritin levels in our patients with RA. However, we could be more cautious about the effects on hemoglobin and ferritin levels in patients with RA while they receive a high dose of vitamin B6 supplementation.
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